UK Supply Chain Disruption Due To Closed Borders Remains A Concern
Manufacturers Are Seeking To Maintain Prices Despite COVID-19 Crisis
The BGMA has emphasized the importance of prioritizing transport of medicines across borders, at the same time as it has praised decisions by the UK competition authority and European Commission to relax rules on co-ordinating to facilitate the supply of medicines.
You may also be interested in...
While the UK’s drugs stockpile is depleting due to high demand caused by the coronavirus pandemic, a no-deal Brexit in January 2021 may further harm medicines supply during a possible second wave of COVID-19.
Sandoz is sponsoring a major hydroxychloroquine trial while other major industry players like Teva, Mylan, Apotex, Stada and Lupin are also accelerating efforts to fight the coronavirus crisis. Accord and Wavelength Pharma have stepped up their manufacturing to meet demand, as the AAM has cancelled its annual meeting.
A temporary framework has been adopted by the European Commission that will allow companies and associations to co-ordinate efforts to tackle the coronavirus pandemic without raising competition concerns. The move has been welcomed by the European off-patent industry.